Company intelligence / Profile preview

BioStar Pharmacia

Ownership: Private
Employees: ~200
Development stage: Commercial

Overview

Utidelone injectable (UTD1) was approved by NMPA in March 2021 for metastatic breast cancer. Phase III clinical trials showed excellent efficacy and safety profile, significantly increasing PFS and OS compared to standard regimens. FDA has approved IND for a phase 2/3 trial of Utidelone for NSCLC.

Therapeutic areas: OncologyInfectious DiseasesGastroenterologyOphthalmologyWomen's Health
Modalities: Small moleculesmicrobial fermentation-derived compounds
Industry: Biotech

Drug pipeline

3 assets

Starmicina

Commercial

Indications: Animal health

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on BioStar Pharmacia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioStar Pharmacia.

Explore the full profile